IQVIA raises 2026 guidance after strong second-quarter bookings and revenue growth
The company posted 8.7% revenue growth and record R&D Solutions bookings, then raised its full-year revenue, EBITDA and EPS guidance.
IQVIA Holdings reported second-quarter 2026 results on July 28, 2026, for the period ended June 30, 2026. Revenue for the quarter was $4,368 million, increasing 8.7% on a reported basis and 8.5% at constant currency compared with the second quarter of 2025.1 Commercial Solutions revenue was $1,793 million, up 8.6% on a reported basis, while Research & Development Solutions revenue was $2,575 million, up 8.8% on a reported basis.1
Bookings were a highlight. Second-quarter net new bookings reached $3.15 billion, a 19% year-over-year increase, producing a book-to-bill ratio of 1.22x, and last-twelve-month net new bookings totaled $11.3 billion, up 13% year-over-year.1 As of June 30, 2026, R&D Solutions contracted backlog stood at $34.2 billion, with the company expecting about $9.2 billion of that backlog to convert to revenue over the next twelve months, a 7.5% year-over-year increase.1
CEO Ari Bousbib said R&D Solutions generated record-level net new bookings of over $3.1 billion and reported 7% organic revenue growth1, and pointed to double digit growth in patient solutions and commercial engagement services, high-single-digit organic growth in analytics and consulting, and increased adoption of AI solutions1 in the Commercial Solutions segment.
On profitability, Adjusted EBITDA was $994 million, up 9.2% year-over-year, and Adjusted Diluted Earnings per Share was $3.15, up 12.1% year-over-year.1
Looking ahead, the company raised its full-year 2026 guidance to revenue between $17,275 million and $17,475 million, Adjusted EBITDA between $4,000 million and $4,050 million, and Adjusted Diluted EPS between $12.80 and $13.00.1 The new revenue guidance midpoint implies 6.5% growth versus the prior guidance of 5.8%, reflecting higher organic growth and a greater contribution from acquisitions, partly offset by unfavorable currency effects.1
On cash position, as of June 30, 2026, cash and cash equivalents were $1,909 million against debt of $15,999 million, for net debt of $14,090 million, with a net leverage ratio of 3.59x trailing twelve-month Adjusted EBITDA.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.